Alzheimer’s Blood Test: What You Need to Know
- The Food and Drug Governance has cleared the first blood test to help diagnose Alzheimer's disease, offering a less invasive option to PET scans and spinal taps.
- In 2025, an estimated 7.2 million Americans ages 65 and older have Alzheimer's dementia.
- The "Lumipulse G pTau217/ß-Amyloid 1-42 Plasma ratio" test is designed for individuals aged 55 and older who exhibit cognitive decline, as confirmed by a clinician.
Discover the groundbreaking Alzheimer’s blood test now cleared by the FDA, paving the way for earlier detection adn treatment of this devastating disease. This cutting-edge test identifies amyloid plaques,a key primary_keyword marker,offering a less invasive option to existing methods. Ideal for individuals 55 and older experiencing cognitive decline, the new test helps confirm the likelihood of Alzheimer’s, possibly enabling patients to access life-altering medications sooner. However, understanding its limitations, including potential false positives, is crucial. News Directory 3 keeps you informed about the latest advancements in healthcare. Learn how this innovative secondary_keyword blood test is set to revolutionize diagnosis and accelerate research. Discover what’s next …
FDA Clears First Blood Test for Alzheimer’s Diagnosis
Updated June 12, 2025
The Food and Drug Governance has cleared the first blood test to help diagnose Alzheimer’s disease, offering a less invasive option to PET scans and spinal taps. The test identifies amyloid plaques,a hallmark of Alzheimer’s,in individuals experiencing cognitive decline.
With an aging population,Alzheimer’s cases are rising. In 2025, an estimated 7.2 million Americans ages 65 and older have Alzheimer’s dementia. The new blood test offers a convenient method to confirm the likelihood of Alzheimer’s when cognitive decline is already apparent.
The “Lumipulse G pTau217/ß-Amyloid 1-42 Plasma ratio” test is designed for individuals aged 55 and older who exhibit cognitive decline, as confirmed by a clinician. Early detection is crucial, according to Dr. Sayad ausim azizi, clinical chief of behavioral neurology and memory disorders at the Yale School of Medicine. He likened the Alzheimer’s brain to a rusty engine, where plaque interferes with function.
While existing treatments cannot remove plaque, they can slow brain degradation by 30% to 40%, extending a patient’s functional lifespan. Dr. Gregg Day, a neurologist with the Mayo clinic in Jacksonville, Florida, who led a study of the blood test, noted that primary care physicians (PCPs) can use the test to determine if a patient should be referred to a specialist. PCPs may also prescribe medications like donepezil to improve mental function.
The test is not intended for general screening, as amyloid plaques can be present without indicating imminent Alzheimer’s. Furthermore, treatments like lecanemab and donanemab carry potential side effects, including infusion-related reactions and, rarely, brain swelling or bleeding.
False positives are possible, as amyloid buildup can be linked to other conditions, such as kidney dysfunction. A Mayo Clinic study showed the test accurately confirmed Alzheimer’s in 95% of those with cognitive symptoms but had a 17.6% false-positive rate. The study also indicated the blood test could help differentiate Alzheimer’s from other forms of dementia.
“It’s a great way of using a biomarker [measurable sign of disease] in the blood to make an earlier diagnosis to give a drug” to slow disease progression.
what’s next
The blood test is expected to advance Alzheimer’s research by providing a more precise understanding of the relationship between clinical symptoms and blood test findings. It can also help track the effectiveness of Alzheimer’s treatments and facilitate evaluations in diverse populations, according to Day.